Related Experiment Video
Updated: Oct 18, 2025
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
Published on: October 4, 2016
Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions
Jean-Philippe Miron1, Véronique Desbeaumes Jodoin2, Paul Lespérance2
1Centre de Recherche du CHUM (CRCHUM), Centre Hospitalier de l'Université de Montréal (CHUM) and Département de Psychiatrie, Faculté de Médecine, Université́ de Montréal, Montréal, QC, Canada Institute of Medical Science and Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada CHUM, 1051 Sanguinet, Montréal, QC, H2X 3E4, Canada.
Repetitive transcranial magnetic stimulation (rTMS) offers a safe treatment for major depressive disorder (MDD), with real-world data showing significant response and remission rates. This review explores its principles, efficacy, and future improvements for wider accessibility and effectiveness.
Area of Science:
- Neuroscience
- Psychiatry
- Medical Technology
Background:
- Repetitive transcranial magnetic stimulation (rTMS) is an established, safe, and well-tolerated intervention for major depressive disorder (MDD).
- Extensive research, including over 150 randomized controlled trials (RCTs) and numerous meta-analyses, has confirmed its efficacy.
- Real-world clinical data further supports rTMS effectiveness, with reported response rates of 40-50% and remission rates of 25-30%.
Purpose of the Study:
- To provide a comprehensive review of repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder (MDD).
- To discuss historical perspectives, basic principles, and current evidence regarding rTMS efficacy and safety.
- To explore strategies for enhancing rTMS accessibility and effectiveness, including treatment personalization and accelerated protocols.
Main Methods:
- Review of existing literature, including randomized controlled trials (RCTs), meta-analyses, and real-world data on rTMS for MDD.
- Analysis of basic principles, including mechanisms, protocols, stimulation targets, and side effects.
- Discussion of potential solutions for increasing accessibility and effectiveness, such as treatment modifications and accelerated scheduling.
Main Results:
- rTMS demonstrates confirmed efficacy for MDD, supported by robust scientific evidence and clinical practice data.
- Current literature indicates response rates of 40-50% and remission rates of 25-30% in real-world settings.
- Various approaches are being explored to improve treatment accessibility and personalize interventions for better outcomes.
Conclusions:
- Repetitive transcranial magnetic stimulation (rTMS) is a validated treatment for major depressive disorder (MDD) with proven efficacy and safety.
- Future directions focus on enhancing treatment accessibility through equipment and protocol modifications, and increasing effectiveness via personalization and accelerated scheduling.
- Accelerated rTMS (arTMS) presents a potential solution for optimizing treatment scheduling and patient outcomes.
